Biggest News Aggregation in the World
๐Ÿ“ฐ Leukemia News

Page 85 - Leukemia News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Leukemia. Real-time updates on events, politics, business and more.

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.
United States Santa Diego Sana Chaudhry Justin Taylor Sylvester Comprehensive Cancer Center Clinical Oncology Program At Sylvester

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
United States Brentl Wood Susanm Obrien Anjalis Advani Aaront Gerds Jeraldp Radich

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.
United States Elias Jabbour Ghayas Issa American Society Of Hematology University Of Texas Md Anderson Cancer Center Janssen Pharmaceuticals

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens โ€“ a major indicator of clinical improvement โ€“ compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
United States Naveen Pemmaraju American Society Of Hematology University Of Texas Md Anderson Cancer Center Manderson Cancer Annual Meeting

New combinations and targeted therapies for acute myeloid leukemia on the horizon

The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.
United States San Diego Justinm Watts University Of Miami Miller School Medicine Sylvester Comprehensive Cancer Center American Cancer Society

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science